Tag Archive for: M&A

Centre de R&D Pierre Fabre, Oncopole, Toulouse
© Don-vip - wikipedia.org

French pharma company Pierre Fabre Laboratories has baged Vertical Bio to push development of the company’s NSCLC candidate.

C

© Novo Nordisk A/S

With a US$1bn acquisition of Canadian Inversago Pharma, Novo Nordisk A/S fiights to maintain its dominant position in the booming weight loss drug market.

RNA production automation by Quantoom Biosciences, part of Univercells group @Univercells

Donaldson Company, Inc. (NYSE: DCI), a heritage provider of innovative filtration products and solutions, announced the acquisition of Univercells Technologies (Belgium), a global provider of innovative biomanufacturing solutions for cell and gene therapy research, development and commercial manufacturing.

EpiTcer platform. Neoantigen-loaded beads are phagocytised by DCs and present antigens to T-cells which in turn are activated. © NEOGAP Therapeutics

Swedish personalised immunotherapy specialist Neogap Therapeutics AB has acquired the remaining shares of its subsidiary, TCER Oncology AB through two new shareholders.

© Ralphs_Fotos/pixabay.com

GI specialist Ironwood Pharmaceuticals Inc. has announced to acquire Swiss VectivBio Holding AG for $17 per share in an all-cash transaction.

© ADL SL

Munich-based Wacker Group has purchased all shares of the Spanish CMO ADL BioPharma from financial investor Kartesia for €100m.

Picture: Stifel Europe Bank AG

From its all-time high in August 2021 the largest and most important index for the biotech industry also in Europe (NBI) lost around 25%. After a period of excessive capital inflows, money is much harder to come by these days. The answer can only be more creativity in structuring deals.

© Aymanejed/pixabay.com

Pfizer strengthens its oncology portfolio by acquiring Seagen, the biotech specialist in antibody-drug conjugates technology.

© BioNTech SE

BioNTech SE will pay £562m in cash to acquire its former partner InstaDeep Ltd. to expand its capabilities in AI-based drug discovery.

The EU Commissioners ©EUC

The European Commission has now recommended concrete steps that, while not yet final, would require Illumina to "swiftly" reverse its controversial $7.1bn acquisition of Grail.